Article

Pharmacometric assessment of the <i>in vivo</i> antiviral activity of ivermectin in early symptomatic COVID-19

2022-07-19

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Background</h4> There is no generally accepted methodology for in vivo assessment of antiviral activity in SARS-CoV-2 infection. Ivermectin has been recommended widely as a treatment of COVID-19, but whether it has significant antiviral activity in vivo is uncertain. <h4>Methods</h4> In a multicentre open label, randomized, controlled adaptive platform trial, adult patients with early s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 24e681ff-1bd8-59f9-8a52-80a275d510c4
DOI: 10.1101/2022.07.15.22277570

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacometric assessment of the <i>in vivo</i> antiviral activity of ivermectin in early symptomatic COVID-19DOI 10.1101/2022.07.15.22277570Read

THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCESemantic proximity Read

THE THERAPEUTIC POTENTIAL OF IVERMECTIN FOR COVID-19: A SYSTEMATIC REVIEW OF MECHANISMS AND EVIDENCESemantic proximity Read

Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replicationSemantic proximity Read

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read

Minimal impact of ivermectin on immune response and transcriptional profiles in naïve adults with mild COVID-19Semantic proximity Read

Research Into Potential Therapies Against COVID-19, With Focus On IvermectinSemantic proximity Read

Research Into Potential Therapies Against COVID-19, With Focus On IvermectinSemantic proximity Read

Galectin antagonist use in mild cases of SARS-CoV-2; pilot feasibility randomised, open label, controlled trialSemantic proximity Read

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity Read

The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trialSemantic proximity Read

Phase 2 dose-ranging study of the virologic efficacy and safety of the combination COVID-19 antibodies casirivimab and imdevimab in the outpatient settingSemantic proximity Read

REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsSemantic proximity Read